<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00862251</url>
  </required_header>
  <id_info>
    <org_study_id>0653A-133</org_study_id>
    <secondary_id>2009_559</secondary_id>
    <nct_id>NCT00862251</nct_id>
  </id_info>
  <brief_title>Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)</brief_title>
  <official_title>A Randomized, Double-Blind, Active-Controlled Study of Patients With Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled With Simvastatin or Atorvastatin: Comparison of Switching to Combination Tablet Ezetimibe/Simvastatin Versus Switching to Rosuvastatin or Doubling the Statin Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of switching to a combination tablet
      ezetimibe/simvastatin (10mg/20mg) versus rosuvastatin (10 mg) versus doubling the statin dose
      in those patients who have cardiovascular disease and diabetes mellitus not adequately
      controlled on simvastatin 20 mg or atorvastatin 10 mg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Statin (Simvastatin or Atorvastatin).</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In Participants Treated With Simvastatin at Baseline, Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Simvastatin</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Participants Treated With Atorvastatin at Baseline, Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Atorvastatin</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Switching Treatment to Rosuvastatin</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Reached the Target LDL-Cholesterol Level of &lt; 70 mg/dL (1.81 mmol/L)</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Participants Treated With Simvastatin at Baseline, Number of Participants Who Reached the Target LDL-Cholesterol Level of &lt; 70 mg/dL (1.81 mmol/L)</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Participants Treated With Atorvastatin at Baseline, Number of Participants Who Reached the Target LDL-Cholesterol Level of &lt; 70 mg/dL (1.81 mmol/L)</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol (TC)</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglycerides</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in LDL-C/HDL-C Ratio</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in TC/HDL-C Ratio</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-HDL-C/HDL-C Ratio</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B (Apo B)</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Apolipoprotein A-I (Apo A-I)</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apo B/Apo A-I Ratio</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP)</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">808</enrollment>
  <condition>Cardiovascular Disorder</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Ezetimibe/simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Doubling statin dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe (+) simvastatin</intervention_name>
    <description>ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks.</description>
    <arm_group_label>Ezetimibe/simvastatin</arm_group_label>
    <other_name>Vytorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin 40 mg or atorvastatin 20 mg</intervention_name>
    <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
    <arm_group_label>Doubling statin dose</arm_group_label>
    <other_name>Lipitor, Zocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin 10 mg or simvastatin 20 mg</intervention_name>
    <description>All patients will take atorvastatin 10 mg tablets OR simvastatin 20 mg tablets, taken once daily in a 6-week screening/stabilization period prior to randomization.</description>
    <arm_group_label>Ezetimibe/simvastatin</arm_group_label>
    <arm_group_label>Doubling statin dose</arm_group_label>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Lipitor, Zocor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has not taken common statins or ezetimibe within 6 weeks of study screening or
             patient is currently taking a daily dose of the following statins for 6 weeks prior to
             study screening: simvastatin, atorvastatin, pravastatin, fluvastatin, ezetimibe,
             lovastatin, or ezetimibe + fluvastatin

          -  Patient is willing to go on a cholesterol and glucose lowering diet for the duration
             of the study

          -  Patient is willing to remain abstinent or use birth control for the duration of the
             study

          -  Patient has Diabetes Mellitus with cardiovascular disease

        Exclusion Criteria:

          -  Patient has sensitivity to certain common statin drugs

          -  Patient is Asian and would not be able to start taking the higher doses of
             rosuvastatin necessary for the study design

          -  Patient consumes more than 2 alcoholic drinks per day

          -  Patient is pregnant or breast-feeding

          -  Patient has been treated with other investigational drugs within 30 days of first
             visit

          -  Patient is currently on prohibited doses of the following statin drugs: rosuvastatin,
             simvastatin, atorvastatin, and pravastatin

          -  Patient has congestive heart failure

          -  Patient has uncontrolled high blood pressure

          -  Patient has kidney disease

          -  Patient has uncontrolled endocrine or metabolic disease which are known to possibly
             increase blood lipoproteins

          -  Patient has diabetes mellitus that is not well controlled

          -  Patient is human immunodeficiency virus (HIV) positive

          -  Patient is currently taking medications that inhibit Cytochrome P450 3A4 (CYP3A4)

          -  Patient is currently taking therapies that would increase the risk of muscle weakness

          -  Patient has been taking certain over- the-counter lipid-lowering agents within 6 weeks
             prior to visit 1

          -  Patient is currently taking psyllium or other fiber-based laxatives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Costa Rica</country>
    <country>Croatia</country>
    <country>Egypt</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Peru</country>
    <country>Portugal</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2009</study_first_submitted>
  <study_first_submitted_qc>March 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2009</study_first_posted>
  <results_first_submitted>February 23, 2012</results_first_submitted>
  <results_first_submitted_qc>February 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 16, 2012</results_first_posted>
  <last_update_submitted>March 17, 2017</last_update_submitted>
  <last_update_submitted_qc>March 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiovascular disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ezetimibe/Simvastatin</title>
          <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
        </group>
        <group group_id="P2">
          <title>Doubling Statin Dose</title>
          <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
        </group>
        <group group_id="P3">
          <title>Rosuvastatin</title>
          <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="322"/>
                <participants group_id="P2" count="162"/>
                <participants group_id="P3" count="324"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="303"/>
                <participants group_id="P2" count="157"/>
                <participants group_id="P3" count="315"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ezetimibe/Simvastatin</title>
          <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
        </group>
        <group group_id="B2">
          <title>Doubling Statin Dose</title>
          <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
        </group>
        <group group_id="B3">
          <title>Rosuvastatin</title>
          <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="322"/>
            <count group_id="B2" value="162"/>
            <count group_id="B3" value="324"/>
            <count group_id="B4" value="808"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.1" spread="8.8"/>
                    <measurement group_id="B2" value="64.7" spread="8.3"/>
                    <measurement group_id="B3" value="63.6" spread="8.4"/>
                    <measurement group_id="B4" value="64.0" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="142"/>
                    <measurement group_id="B4" value="386"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="182"/>
                    <measurement group_id="B4" value="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Statin (Simvastatin or Atorvastatin).</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Statin (Simvastatin or Atorvastatin).</title>
          <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.13" lower_limit="-25.95" upper_limit="-20.31"/>
                    <measurement group_id="O2" value="-8.37" lower_limit="-12.32" upper_limit="-4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Percent change in least-square means</param_type>
            <param_value>-14.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.61</ci_lower_limit>
            <ci_upper_limit>-9.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In Participants Treated With Simvastatin at Baseline, Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Simvastatin</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Analysis performed on subpopulation of participants who were previously treated with simvastatin 20 mg and were switched to either Ezetimibe/simvastatin or had simvastatin dose doubled to 40 mg</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Simvastatin Dose</title>
            <description>simvastatin 40 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>In Participants Treated With Simvastatin at Baseline, Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Simvastatin</title>
          <population>Analysis performed on subpopulation of participants who were previously treated with simvastatin 20 mg and were switched to either Ezetimibe/simvastatin or had simvastatin dose doubled to 40 mg</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.59" lower_limit="-25.54" upper_limit="-17.65"/>
                    <measurement group_id="O2" value="-7.98" lower_limit="-13.57" upper_limit="-2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Percent change in Least Square Means</param_type>
            <param_value>-13.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.44</ci_lower_limit>
            <ci_upper_limit>-6.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In Participants Treated With Atorvastatin at Baseline, Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Atorvastatin</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Analysis performed on subpopulation of participants who were previously treated with atorvastatin 10 mg and were switched to either Ezetimibe/simvastatin or had atorvastatin dose doubled to 20 mg</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Atorvastatin Dose</title>
            <description>atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>In Participants Treated With Atorvastatin at Baseline, Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Atorvastatin</title>
          <population>Analysis performed on subpopulation of participants who were previously treated with atorvastatin 10 mg and were switched to either Ezetimibe/simvastatin or had atorvastatin dose doubled to 20 mg</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.58" lower_limit="-28.63" upper_limit="-20.53"/>
                    <measurement group_id="O2" value="-8.85" lower_limit="-14.47" upper_limit="-3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal Data Analysis (LDA)</method>
            <param_type>Percent change in least squares mean</param_type>
            <param_value>-15.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.65</ci_lower_limit>
            <ci_upper_limit>-8.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Switching Treatment to Rosuvastatin</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Efficacy data were analyzed primarily based upon the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Switching Treatment to Rosuvastatin</title>
          <population>Efficacy data were analyzed primarily based upon the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.13" lower_limit="-25.95" upper_limit="-20.31"/>
                    <measurement group_id="O2" value="-19.32" lower_limit="-22.14" upper_limit="-16.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.060</p_value>
            <method>Longitudinal Data Analysis</method>
            <param_type>Percent Change in Least Squares Means</param_type>
            <param_value>-3.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.78</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Reached the Target LDL-Cholesterol Level of &lt; 70 mg/dL (1.81 mmol/L)</title>
        <time_frame>Week 6</time_frame>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Reached the Target LDL-Cholesterol Level of &lt; 70 mg/dL (1.81 mmol/L)</title>
          <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.5</ci_lower_limit>
            <ci_upper_limit>6.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In Participants Treated With Simvastatin at Baseline, Number of Participants Who Reached the Target LDL-Cholesterol Level of &lt; 70 mg/dL (1.81 mmol/L)</title>
        <time_frame>Week 6</time_frame>
        <population>Analysis performed on subpopulation of participants who were previously treated with simvastatin 20 mg and were switched to either Ezetimibe/simvastatin or had simvastatin dose doubled to 40 mg</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Simvastatin Dose</title>
            <description>simvastatin 40 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>In Participants Treated With Simvastatin at Baseline, Number of Participants Who Reached the Target LDL-Cholesterol Level of &lt; 70 mg/dL (1.81 mmol/L)</title>
          <population>Analysis performed on subpopulation of participants who were previously treated with simvastatin 20 mg and were switched to either Ezetimibe/simvastatin or had simvastatin dose doubled to 40 mg</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.3</ci_lower_limit>
            <ci_upper_limit>8.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In Participants Treated With Atorvastatin at Baseline, Number of Participants Who Reached the Target LDL-Cholesterol Level of &lt; 70 mg/dL (1.81 mmol/L)</title>
        <time_frame>Week 6</time_frame>
        <population>Analysis performed on subpopulation of participants who were previously treated with atorvastatin 10 mg and were switched to either Ezetimibe/simvastatin or had atorvastatin dose doubled to 20 mg</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Atorvastatin Dose</title>
            <description>atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>In Participants Treated With Atorvastatin at Baseline, Number of Participants Who Reached the Target LDL-Cholesterol Level of &lt; 70 mg/dL (1.81 mmol/L)</title>
          <population>Analysis performed on subpopulation of participants who were previously treated with atorvastatin 10 mg and were switched to either Ezetimibe/simvastatin or had atorvastatin dose doubled to 20 mg</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.9</ci_lower_limit>
            <ci_upper_limit>6.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol (TC)</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol (TC)</title>
          <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.21" spread="17.69" lower_limit="-14.99" upper_limit="-11.43"/>
                    <measurement group_id="O2" value="-4.88" spread="15.14" lower_limit="-7.37" upper_limit="-2.39"/>
                    <measurement group_id="O3" value="-10.58" spread="15.18" lower_limit="-12.36" upper_limit="-8.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-8.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.38</ci_lower_limit>
            <ci_upper_limit>-5.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.13</ci_lower_limit>
            <ci_upper_limit>-0.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglycerides</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglycerides</title>
          <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.51" lower_limit="-8.75" upper_limit="-2.15"/>
                    <measurement group_id="O2" value="-2.63" lower_limit="-7.23" upper_limit="2.21"/>
                    <measurement group_id="O3" value="-3.35" lower_limit="-6.66" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.316</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.53</ci_lower_limit>
            <ci_upper_limit>2.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.356</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.75</ci_lower_limit>
            <ci_upper_limit>2.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)</title>
          <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" lower_limit="-0.27" upper_limit="3.21"/>
                    <measurement group_id="O2" value="1.00" lower_limit="-1.43" upper_limit="3.43"/>
                    <measurement group_id="O3" value="1.99" lower_limit="0.26" upper_limit="3.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.756</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.50</ci_lower_limit>
            <ci_upper_limit>3.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.675</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Sqares Mean Difference</param_type>
            <param_value>-0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.96</ci_lower_limit>
            <ci_upper_limit>1.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)</title>
          <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.39" lower_limit="-20.90" upper_limit="-15.88"/>
                    <measurement group_id="O2" value="-6.77" lower_limit="-10.29" upper_limit="-3.25"/>
                    <measurement group_id="O3" value="-15.14" lower_limit="-17.72" upper_limit="-12.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-11.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.93</ci_lower_limit>
            <ci_upper_limit>-7.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.078</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-3.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.71</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in LDL-C/HDL-C Ratio</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in LDL-C/HDL-C Ratio</title>
          <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.55" lower_limit="-25.09" upper_limit="-18.01"/>
                    <measurement group_id="O2" value="-7.39" lower_limit="-12.34" upper_limit="-2.43"/>
                    <measurement group_id="O3" value="-18.99" lower_limit="-22.52" upper_limit="-15.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-14.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.23</ci_lower_limit>
            <ci_upper_limit>-8.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.313</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Sqares Mean Difference</param_type>
            <param_value>-2.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.53</ci_lower_limit>
            <ci_upper_limit>2.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in TC/HDL-C Ratio</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in TC/HDL-C Ratio</title>
          <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.52" lower_limit="-14.83" upper_limit="-10.22"/>
                    <measurement group_id="O2" value="-4.36" lower_limit="-7.58" upper_limit="-1.14"/>
                    <measurement group_id="O3" value="-10.70" lower_limit="-12.99" upper_limit="-8.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-8.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.10</ci_lower_limit>
            <ci_upper_limit>-4.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.266</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.05</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-HDL-C/HDL-C Ratio</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-HDL-C/HDL-C Ratio</title>
          <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.77" lower_limit="-20.09" upper_limit="-13.45"/>
                    <measurement group_id="O2" value="-5.32" lower_limit="-9.98" upper_limit="-0.66"/>
                    <measurement group_id="O3" value="-14.64" lower_limit="-17.95" upper_limit="-11.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-11.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.16</ci_lower_limit>
            <ci_upper_limit>-5.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.371</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.81</ci_lower_limit>
            <ci_upper_limit>2.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B (Apo B)</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B (Apo B)</title>
          <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="313"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.98" lower_limit="-16.99" upper_limit="-12.97"/>
                    <measurement group_id="O2" value="-6.97" lower_limit="-9.78" upper_limit="-4.15"/>
                    <measurement group_id="O3" value="-12.03" lower_limit="-14.05" upper_limit="-10.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-8.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.46</ci_lower_limit>
            <ci_upper_limit>-4.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.041</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.78</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Apolipoprotein A-I (Apo A-I)</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Apolipoprotein A-I (Apo A-I)</title>
          <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="313"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" lower_limit="-0.84" upper_limit="2.11"/>
                    <measurement group_id="O2" value="-0.93" lower_limit="-2.99" upper_limit="1.12"/>
                    <measurement group_id="O3" value="0.86" lower_limit="-0.62" upper_limit="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.218</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.93</ci_lower_limit>
            <ci_upper_limit>4.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.832</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.27</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apo B/Apo A-I Ratio</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apo B/Apo A-I Ratio</title>
          <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="313"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.67" lower_limit="-16.27" upper_limit="-11.06"/>
                    <measurement group_id="O2" value="-4.75" lower_limit="-8.39" upper_limit="-1.11"/>
                    <measurement group_id="O3" value="-11.14" lower_limit="-13.75" upper_limit="-8.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-8.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.36</ci_lower_limit>
            <ci_upper_limit>-4.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.175</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.17</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP)</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP)</title>
          <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="313"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.42" lower_limit="-13.94" upper_limit="6.15"/>
                    <measurement group_id="O2" value="-1.64" lower_limit="-14.93" upper_limit="13.74"/>
                    <measurement group_id="O3" value="-9.11" lower_limit="-18.13" upper_limit="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.749</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.88</ci_lower_limit>
            <ci_upper_limit>14.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.494</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>4.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.73</ci_lower_limit>
            <ci_upper_limit>18.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All Patients as Treated (APaT) population was used for the analysis of safety data. The APaT population consisted of all randomized patients who received at
least one dose of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ezetimibe/Simvastatin</title>
          <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
        </group>
        <group group_id="E2">
          <title>Doubling Statin Dose</title>
          <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
        </group>
        <group group_id="E3">
          <title>Rosuvastatin</title>
          <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial thrombosis limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>An investigator and/or his/her colleagues may publish the results for their study site independently after the multicenter publication, or 24 months after completion of the study, whichever comes first. The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President,Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

